Acasti Pharma Inc – Class A (NASDAQ:ACST) Sellers Increased Their Shorts By 21.41% As Of Dec 8, 2018

Acasti Pharma Inc. (NASDAQ:ACST) Corporate Logo

It was noted an increase on Acasti Pharma Inc – Class A (NASDAQ:ACST)’s shares shorted with 21.41%. It was announced in December by FINRA the 520,500 shares shorted on ACST. Previously was reported up change of 21.41% from 428,700 shares. With Average volume 172,400, ACST’s previous position will take 3 days to restore.

The stock decreased 1.71% or $0.0116 during the last trading session, hitting $0.6658.Currently Acasti Pharma Inc. is downtrending after 57.02% change in last December 8, 2017. ACST has also 361,251 shares volume. The stock underperformed the S&P 500 by 72.64%.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases.The company has $52.56 million market cap. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia.Currently it has negative earnings.

For more Acasti Pharma Inc. (NASDAQ:ACST) news posted recently go to: Globenewswire.com, Nasdaq.com, Seekingalpha.com, Marketwired.com or Globenewswire.com. The titles are as follows: “Acasti Pharma Awarded Composition-of-Matter Patent by the U.S. Patent and Trademark Office – GlobeNewswire” posted on July 24, 2018, “Health Care Sector Update for 10/04/2018: ACST,ACST.V,ALNY,TLRY – Nasdaq” on October 04, 2018, “Acasti Pharma closes $19.1M common stock offering – Seeking Alpha” with a publish date: October 11, 2018, “Acasti Pharma Clarifies Term of Proposed Strategic Partnership with Leading China Pharmaceutical Company – Marketwired” and the last “Acasti Pharma Appoints Brian Groch as Chief Commercial Officer – GlobeNewswire” with publication date: June 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.